Glenmark Pharma
May 25, 2012 at 08:19 | Source: Moneycontrol.com
May 16, 2012 at 12:24 | Source: Moneycontrol.com
May 12, 2012 at 13:51 | Source: Moneycontrol.com
May 11, 2012 at 10:08 | Source: CNBC-TV18
May 11, 2012 at 08:43 | Source: CNBC-TV18
May 10, 2012 at 18:34 | Source: CNBC-TV18
News across the web »
May 24, 2012 at 13:21 | Source: FirstPost
May 14, 2012 at 12:46 | Source: FirstPost
May 14, 2012 at 12:11 | Source: FirstPost
May 11, 2012 at 20:00 | Source: The Hindu BusinessLine
May 08, 2012 at 12:31 | Source: FirstPost
Interact & exchange stock tips & market info »
Related News »
Glenmark Pharma has registered excellent numbers for the quarter ending March 2012. The consolidated sales surged to Rs.1066.20 crore, up 34% for the March 2012 quarter as against Rs.795.60 crore during the corresponding quarter previous year ...
May 25, 2012 at 15:13 | Source: equitybulls.com
Glenmark Pharma 's US generics arm has received tentative approval from US Food and Drugs Administration (FDA) for Zolmitriptan orally disintegrating tablets, its copy of AstraZeneca's ZomigZMT tablets. The drug is used to treat acute migraine attacks.
May 16, 2012 at 06:42 | Source: MoneyControl.com
It’s a short sell." “Buy Glenmark Pharma with a target of Rs 385-390. Glenmark could be one exceptional stock that could go up in a falling market but time it well. It’s a good intraday trade, even today, on the long side.”
May 16, 2012 at 06:42 | Source: MoneyControl.com
Glenmark Pharma to outlicense NCEs 01-DEC-09 Glenmark Pharmaceuticals is confident of outlicensing at least one of its new chemical entities (NCEs) under development before the end of this financial year, according to the chief executive and managing ...
May 24, 2012 at 19:32 | Source: Business Standard
Growth implied; next task sustainability... Glenmark reported better than expected Q4FY12 numbers. Revenues grew ~34% YoY and ~3% QoQ to Rs.1066 crore (higher than our expectation of Rs.973 crore), driven by both generics and speciality businesses.
May 11, 2012 at 16:49 | Source: equitybulls.com
Indian pharma stocks are trading mixed. Fresensius Kabi Onco. And Orchid Chemicals are the top gainers while Panacea Biotech and Biocon are losing the maximum. As per a leading daily, Glenmark Pharma is adopting a strategy to tap niche segments instead of ...
May 21, 2012 at 16:58 | Source: MSN India
Indian pharma stocks have opened the day on a mixed note with Ranbaxy Laboratories, Sun Pharma and Indoco Remedies leading the losses. However, Glenmark Pharma and J B Chemicals are trading firm. As per a leading financial daily, Indian drug maker Dr Reddy ...
May 22, 2012 at 16:57 | Source: MSN India
Among frontline companies, all acute focused companies, including Glenmark Pharmaceuticals Ltd, Pfizer Ltd and GlaxoSmithKline Pharmaceuticals Ltd, significantly outperformed the industry because of strong recovery in segments such as anti-infective ...
May 23, 2012 at 17:17 | Source: Livemint.com
Indian drugmakers such as Glenmark, Lupin, Sun Pharma and Dr Reddy’s that are trying to make a mark with niche and complex therapies in the US, face price discounting and heavy competition. Complex therapies refer to therapeutic categories like ...
May 25, 2012 at 03:25 | Source: Daily News and Analysis
Hexaware and Glenmark Pharma also gained about 5 percent each. Power Finance Corporation rose closed up 0.8 percent after net profit rose 34.69 percent to Rs 818.30 crore and total income rose 40.44 percent to Rs 3,684.29 crore in the fourth ...
May 22, 2012 at 10:38 | Source: firstpost.com